Summary Patients with T2 grade 3 and T3 bladder cancer were randomised to be treated with radiation alone (NO MISO) or with radiation and misonidazole (PLUS MISO). Patients in both groups initially received 40 Gy in 2 Gy fractions (5/week). Patients in the NO MISO arm received a further 20 Gy in 2 Gy fractions (5/week). Patients in the PLUS MISO arm received a further 12 Gy in 6 Gy fractions (1/week).
Misonidazole (MISO) has been experimentally shown to sensitise hypoxic tumour cells to irradiation both in vitro and in vivo (Adams, 1978) . The sensitiser enhancement ratio of MISO is dependent on the tumour concentration of the drug (Asquith et al., 1974) . In clinical studies of fractionated radiation the total amount of MISO which can be administered is limited by the drug's neurotoxicity (peripheral neuropathy) (Dische et al., 1979) , and patients have been treated at low tumour concentrations of MISO. In patients with bladder carcinoma, high tumour concentrations of MISO are obtainable after intravesical administration (Awwad et al., 1983) . A treatment regimen was devised in which an initial course of conventionally fractionated radiation was followed by two administrations of oral and intravesical MISO plus large fractions of radiation (Abratt, 1982) . The regimen was designed with the specific aim of achieving high tumour concentrations of MISO. The aim was to radiosensitise and sterilise clonogenic hypoxic cells persisting after conventionally fractionated radiation.
The results of a pilot study of this regimen was apparently better than that in a series of historical controls (Abratt et al., 1983; Abratt et al., 1987) . This report described the final results of a prospective randomised study with a minimum follow-up in surviving patients of 5 years. The initial results of the study with the minimum follow up of 6 months have been reported (Abratt et al., 1987 complete response rate from 40% to 75% is 48 (one sided test, P = 0.05 with a power of 0.80). The number of patients needed to detect an increase in survival rate with bladder preservation from 25% to 50% is 56 (one sided test, P = 0.05 with a power of 0.80) (Machin & Campbell, 1987) . The power of the latter test with 53 evaluable patients in this study is 0.76 (Machin & Campbell, 1987) .
Results
In the NO -MISO and PLUS MISO arms, the complete response rate at cystoscopy at 6 months was 63% and 69%, the 5-year survival rate was 41% and 48%, the 5-year control rate with bladder preservation was 46% and 36% respectively when the data was censored for death from metastases while locally clear, and 36% and 31% respectively when the data was not censored for metastases (see Table II ). None of these differences is statistically significant (chi square and logrank). The outcome of patients who had a complete response at cystoscopy is shown (see Table III ). In the NO MISO and PLUS MISO arm, 64% and 56% of these patients respectively remained clear of all disease at follow-up at 5 years or until they died of intercurrent disease. The local relapse rate was 18% and 38% respectively. The 5-year survival rate was statistically better (log rank test) in patients with, as compared to those without, a complete response for all patients (68% and 6%, P<0.001), in the PLUS MISO arm (72% and 0%, P<0.001) and in the NO MISO arm (63% and 10%, P<0.01).
Two patients had Grade 3 RTOG late bowel complications, that is obstruction or bleeding requiring surgery. Both these patients who were in the PLUS MISO arm, had undergone salvage cystectomy and subsequently required colostomies for bowel obstruction. The 5-year complication rate (RTOG Grade 3) was 9% (life table method). In addition, two patients in the PLUS MISO arm developed wound sepsis post cystectomy. No patients had severe late bladder complications. There was no MISO related neurotoxicity. Salvage cystectomies were undertaken in 15 patients. A complete response at cystoscopy was noted in nine of these patients and they had undergone cystectomy for tumour recurrence. Seven of these patients were in the PLUS MISO arm. Their median time to recurrence was 19 months (range = 12 to 25 months).
The 5-year survival rate in patients undergoing salvage cystectomy was 44%. The 5-year survival rate for patients with and without a complete response at cystoscopy at 6 months was 65.8% and 17% respectively. In the nine patients who had a complete response and subsequently had a cystectomy, five (55%) are clear, two (22%) failed with metastases only, and two (22%) failed locally. In the six patients who failed to have a complete response, one (17%) is alive and clear, two (33%) failed with metastases and three (50%) failed locally.
Discussion
A high tumour concentration of MISO was found in cystectomy specimens of patients with bladder cancer after intravesical MISO administration (Awwad et al., 1983) . Analogous studies in experimental mice have also resulted in high tumour concentrations of MISO (Fathi et al., 1983) . It has also been shown in our previous study that serum levels of MISO after oral and intravesical administration were not higher than those after oral administration only (Abratt et al., 1983) . It therefore appeared that increased tumour radiosensitisation could be obtained without increased neurotoxicity.
MISO can, however, only be administered at this high concentration for a part of the course of fractionated radiation. It was shown in mouse studies that MISO will not improve tumour control probabilities for the optimum radiation fractionation schedule in a reoxygenating tumour, although the drug is of benefit for all fractionation schedules when a poorly reoxygenating tumour was studied (Fowler et al., 1976; Sheldon & Fowler, 1978) . It was hypothesised in this study that reoxygenation might take place during the intial course of fractionated radiation, but fail towards the end of therapy because of the effect of radiation on the tumour vasculature (Abratt, 1982) . This hypothesis was not, however, supported by the findings in this study, even though the number of patients entered in the study was relatively low. A large difference in response rate or survival rate with bladder preservation between the two groups would be required to be detected with a power of more than 0.80.
There are many possible reasons for failing to obtain a gain with the use of MISO in this study. These would include inefficient sensitisation, reoxygenation throughout the course of radiation, a low proportion of hypoxic cells during treatment, and tumour heterogeneity with intrinsic cell radioresistance. In addition, the size of the large fractions in the PLUS MISO arm was based on a clinical estimation of large bowel tolerance. The radiation regimen used in the PLUS MISO arm may be biologically inferior to the NO MISO arm as regards tumour control as indicated by the linear quadratic model (Fowler, 1989) . The biological effective dose (BED) to the coned down volume in the NO MISO (2 Gy x 10) and MISO (6 Gy x 2) arms would be 24 Gylo and 19, 2 Gylo respectively, assuming an alpha beta ratio of 10 for tumour control, ignoring cell proliferation. The BED to the coned down volume in both the NO MISO and PLUS MISO arms would be 30 Gy4, assuming an alpha beta ratio of 4, similar to late reacting tissue for the subpopulation of chronically hypoxic clonagenic cells. It was assumed as well in the PLUS MISO regimen that the persisting chronically hypoxic cells would not be repopulating while rapid repopulation may be taking place.
The late complication rate was closely monitored in this study because of the use of large radiation fractions with MISO, even though this was given to coned down volumes only. No increased late complications were seen in patients treated with radiation and MISO alone. In the patients who, however, subsequently required a cystectomy, there does appear to be increased morbidity. In our earlier pilot study, the only patient with an RTOG Grade 3 late complication also had undergone a cystectomy and subsequently required a colostomy for bowel obstruction. It is spectulated that the limited use of large radiation fractions in this study resulted in patients reaching the limit of tissue tolerance and that morbidity was precipitated by salvage cystectomy.
In the two previously reported prospective studies of radiation, with or without MISO as primary treatment for bladder cancer, MISO was used orally only (Awwad et al., 1984; Papavasilou et al., 1983) . In neither study was there a statistically significant difference between the tumour response rate or recurrence-free survival in the patients treated with or without MISO.
Radical irradiation with surveillance cystoscopy and salvage cystectomy can be an effective form of therapy in patients with bladder cancer with 25% to 50% of patients being locally disease-free with preserved bladders at followup. Factors which predict a favourable outcome have been discussed (Shipley et al., 1985) . We have not been able to show additional benefit from oral and intravesical MISO in this prospective randomised trial. Improved sensitisers have been developed for clinical investigation. Their optimal use required a better understanding of the pattern of tumour reoxygenation in clinical radiotherapy.
